![]() |
Immobilized Recombinant Human CD19 Protein (ECD, Fc Tag) (Cat: 11880-H02W) at 2 μg/mL (100 μL/well) can bind Anti-CD19 (Research Grade Inebilizumab Biosimilar), the EC50 is 3.4-10 ng/mL(Routinely tested). |
The purity of Recombinant Human CD19 Protein, ECD, Fc Tag, HPLC-verified (Cat. No. 11880-H02W) was more than 90% and the molecular weight of this protein is around 143.2 kDa verified by SEC-MALS (Routinely tested). |
Loaded Biotinylated Anti-CD19 (Research Grade Inebilizumab Biosimilar) on SA Biosensor, can bind Recombinant Human CD19 Protein, hFc Tag (Cat. No. 11880-H02W) with an affinity constant of 0.575 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). |
Immobilized Recombinant Human CD19 Protein (ECD, Fc Tag) (Cat: 11880-H02W) at 2 μg/mL (100 μL/well) can bind Anti-CD19 (Research Grade Inebilizumab Biosimilar), Biotinylated, the EC50 is 1-4 ng/mL(QC tested). |
Cancer Drug Targets
Zola H, et al. (2007) CD molecules 2006-human cell differentiation molecules. J Immunol Methods. 318 (1-2): 1-5.
Ho IC, et al. (2009) GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol. 9 (2): 125-35.
Matesanz-Isabel J, et al. (2011) New B-cell CD molecules. Immunology Letters.134 (2): 104-12.
Carter RH, et al. (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 256 (5053): 105-7.
400-829-0116